Pharmacokinetic/pharmacodynamic modeling in drug research and development

Journal of Clinical Pharmacology

Volumn 40, Issue 12 II, 2000, Pages 1399-1418

  Derendorf, Hartmut ^a   Lesko, Lawrence J ^b   Chaikin, Philip ^c   Colburn, Wayne A ^d   Lee, Peter ^b   Miller, Raymond ^e   Powell, Robert ^e   Rhodes, Gerald ^c   Stanski, Donald ^f   Venitz, Jürgen ^g  

^a UNIVERSITY OF FLORIDA   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c SANOFI   (France)

^d MDS Inc   (Canada)

^e PFIZER INC   (United States)

^f Pharsight   (United States)

^g VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

CONCENTRATION RESPONSE; CONFERENCE PAPER; DOSE CALCULATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESEARCH; DRUG RESPONSE; HUMAN; MODEL; PHARMACODYNAMICS;

DRUG DESIGN; DRUG THERAPY; HUMANS; MODELS, BIOLOGICAL; PHARMACOKINETICS; PHARMACOLOGY, CLINICAL; PROTEIN BINDING; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0033730929     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/009127000004001211     Document Type: Article

References (69)

1. Kinetics of drug action: An overview
2. Kinetics of pharmacological response
3. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: Concepts and perspectives
4. ICH, Guideline E4: Dose-response information to support drug registration
5. Drugs and endogenous ligands compete for receptor occupancy
6. Stereochemical aspects of warfarin drug interactions: Use of a combined pharmacokinetic-pharmacodynamic model
7. Pharmacokinetic-pharmacodynamic analysis of unbound disopyramide directly measured in serial plasma samples in man
8. Mathematical modeling of cortisol circadian rhythm and cortisol suppression
9. Efficacy measures: Surrogates or clinical outcomes
10. Surrogate biochemical markers: Precise measurement for strategic drug and biologics development
11. An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development
12. Analytical method validation: Bioavailability, bioequivalence, and pharmacokinetic studies
13. Selecting and validating biologic markers for drug development
14. Time course of drug effect
15. The relationship between antidepressant response and tricyclic antidepressant plasma concentrations: A retrospective analysis of the literature using logistic regression analysis
16. A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data
17. Life tables with concomitant information
18. Regression models and life tables
19. Use of statistical models in assessing the relationships among pharmacokinetic variables, clinical variables, laboratory variables and outcome
20. Application of relative risk regression models to pharmacodynamic studies
21. Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate
22. Population pharmacodynamics of romazarit
23. Trimoprostil plasma concentration - Gastric acid inhibition relationships: Potentiation by food
24. Pharmacokinetic-pharmacodynamic modeling of reversible drug effects
25. Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models
26. Receptor-based pharmacokinetic-pharmacodynamic analysis of corticosteroids
27. Population pharmacokinetics/dynamics
28. Dose optimization based on pharmacokinetic/pharmacodynamic modeling
29. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modeling
30. Pharmacokinetic/dynamic correlation of pulmonary and cardiac effects of fenoterol in asthmatic patients after different routes of administration
31. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine
32. Kinetics of interaction between drugs and biological systems
33. Kinetics of pharmacologic effects in man: The anticoagulant action of warfarin
34. Comparison of four basic models of indirect pharmacodynamic responses
35. Characteristics of indirect pharmacodynamic models and application to clinical drug responses
36. A general conceptual model for non-steady state pharmacokinetic/pharmacodynamic data
37. Further notes on physiologic indirect response models
38. The time of maximum effect for model selection in pharmacokinetic-pharmacodynamic analysis applied to frusemide
39. Third-generation model for corticosteroid pharmacodynamics: Roles of glucocorticoid receptor mRNA and tyrosine aminotransferase mRNA in rat liver
40. Second generation model for prednisolone pharmacodynamics in the rat
41. Receptor-based pharmacokinetic-pharmacodynamic analysis of corticosteroids
42. Pharmacodynamic modeling of the in vivo interaction between cefotaxime and ofloxacin by using serum ultrafiltrate inhibitory titers
43. A general model for time-dissociated pharmacokinetic-pharmacodynamic relationships exemplified by paclitaxel myelosuppression
44. Pharmacokinetic-pharmacodynamic modelling of the in vitro antiinfective effect of piperacillin-tazobactam combinations
45. Population pharmacodynamic model for ketorolac analgesia
46. A pharmacokinetic-pharmacodynamic model for quantal responses with thiopental
47. Kinetics of drug effects in man
48. Mechanism-based pharmacodynamic modeling
49. Some general estimation methods for nonlinear mixed-effects models
50. Pharmacokinetic/pharmacodynamic modeling: What it is! J Pharmacokinet Biopharm
51. Pharmacometrics: Designs for population pharmacodynamics: Value of pharmacokinetic data and population analysis
52. Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients
53. Population pharmacokinetic/pharmacodynamic methodology and applications: A bibliography
54. The use of population pharmacokinetics in drug development
55. ICH, Guideline E5: Ethnic factors in the acceptability of foreign clinical data
56. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development
57. Pharmacodynamic modelling: Application to new drug development
58. The target concentration approach to clinical drug development
59. Relevance of the application of pharmacokinetic-pharmacodynamic modeling concepts in drug development
60. Role of pharmacokinetic-pharmacodynamic principles in rational and cost-effective drug development
61. Clinical trial simulation: Streamlining your drug development process
62. Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modeling
63. PK/PD modeling approach to support clinical development of a long-acting interferon (RO 25-3036) for the treatment of chronic hepatitis C